{"name":"Exelixis","slug":"exelixis","ticker":"EXEL","exchange":"NASDAQ","domain":"exelixis.com","description":"Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.","hq":"Alameda, CA","founded":0,"employees":"1077","ceo":"Michael Morrissey","sector":"Oncology Biotech","stockPrice":44.27,"stockChange":0.28,"stockChangePercent":0.64,"marketCap":"$11.9B","metrics":{"revenue":2200000000,"revenueGrowth":5.6,"grossMargin":96.4,"rdSpend":825001000,"netIncome":782570000,"cash":1059091008,"dividendYield":0,"peRatio":15.9,"fiscalYear":"FY2017"},"revenueBreakdown":[{"name":"Cometriq","genericName":"Cabometyx","slug":"cabometyx","revenue":2200000000,"yoyGrowth":0,"percentOfTotal":100}],"timeline":[{"date":"2012-01-01","label":"Cometriq first approved","drug":"Cometriq","drugSlug":"cabometyx","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Cabozantinib patent cliff ($1.4B at risk)","drug":"Cabozantinib","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":2200000000,"percentOfTotal":100,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"Cometriq","genericName":"Cabometyx","slug":"cabometyx","indication":"Progressive, Metastatic Medullary Thyroid Cancer","status":"marketed","revenue":2200000000},{"name":"Cabozantinib tablets","genericName":"Cabozantinib tablets","slug":"cabozantinib-tablets","indication":"Metastatic renal cell carcinoma","status":"phase_3"},{"name":"Cometriq","genericName":"CABOZANTINIB","slug":"cabozantinib","indication":"Progressive, Metastatic Medullary Thyroid Cancer","status":"marketed"},{"name":"Everolimus (Afinitor) tablets","genericName":"Everolimus (Afinitor) tablets","slug":"everolimus-afinitor-tablets","indication":"Advanced renal cell carcinoma","status":"phase_3"},{"name":"XL184","genericName":"XL184","slug":"xl184","indication":"Metastatic medullary thyroid cancer","status":"phase_3"}]}],"pipeline":[{"name":"Cometriq","genericName":"Cabometyx","slug":"cabometyx","phase":"marketed","mechanism":"Cometriq blocks the VEGFR2 pathway to prevent tumor growth and angiogenesis.","indications":["Progressive, Metastatic Medullary Thyroid Cancer"],"catalyst":""},{"name":"Cabozantinib tablets","genericName":"Cabozantinib tablets","slug":"cabozantinib-tablets","phase":"phase_3","mechanism":"Cabozantinib is a multi-targeted tyrosine kinase inhibitor that blocks MET, VEGFR2, and AXL signaling to inhibit tumor growth and angiogenesis.","indications":["Metastatic renal cell carcinoma","Hepatocellular carcinoma","Medullary thyroid cancer","Castration-resistant prostate cancer"],"catalyst":""},{"name":"Cometriq","genericName":"CABOZANTINIB","slug":"cabozantinib","phase":"marketed","mechanism":"Cometriq works by blocking the activity of vascular endothelial growth factor receptor 2, a protein involved in tumor growth and angiogenesis.","indications":["Progressive, Metastatic Medullary Thyroid Cancer"],"catalyst":""},{"name":"Everolimus (Afinitor) tablets","genericName":"Everolimus (Afinitor) tablets","slug":"everolimus-afinitor-tablets","phase":"phase_3","mechanism":"Everolimus inhibits mTOR (mammalian target of rapamycin), a protein kinase that controls cell growth and proliferation.","indications":["Advanced renal cell carcinoma","Advanced pancreatic neuroendocrine tumors","Hormone receptor-positive, HER2-negative advanced breast cancer","Subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex"],"catalyst":""},{"name":"XL184","genericName":"XL184","slug":"xl184","phase":"phase_3","mechanism":"XL184 is a multi-targeted tyrosine kinase inhibitor that blocks MET, VEGFR2, and RET signaling to inhibit tumor growth and angiogenesis.","indications":["Metastatic medullary thyroid cancer","Renal cell carcinoma","Hepatocellular carcinoma"],"catalyst":""}],"recentEvents":[{"date":"2023-02-23","type":"regulatory","headline":"Exelixis Announces FDA Approval of Cabozantinib for HCC","summary":"The FDA approved Cabozantinib for the treatment of hepatocellular carcinoma (HCC) in patients who have been previously treated with sorafenib.","drugName":"Cabozantinib","sentiment":"positive"},{"date":"2022-02-24","type":"earnings","headline":"Exelixis Reports Fourth Quarter and Full Year 2021 Financial Results","summary":"Exelixis reported its fourth quarter and full year 2021 financial results, with revenue of $1.04 billion and a net loss of $1.04 billion.","drugName":"","sentiment":"neutral"},{"date":"2021-01-11","type":"deal","headline":"Exelixis and Ipsen Announce Collaboration to Develop and Commercialize Cabozantinib in Europe","summary":"Exelixis and Ipsen announced a collaboration to develop and commercialize Cabozantinib in Europe.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxORG1SUjFDUU1abU9RSVhoTEZsN1YyaEFqQTZvVmpScjZMdHBXbjVpSnpRRk1PN0RZbmtINW9vZy1VbzJzZmJqQXNPREVPa3lqQXVpVkhZcTc4U3JUdjVGN2VlWDBMY1JwR2t3dHUwRWhCYXNFWVFCSVRLbzh3dVZWWGdHZWY4VWRXWjRLanliaXBVZmppREdUMS1ydnVaMFFJM0NnTU95NTdwbVd4OUFneXRUWVVPZw?oc=5","date":"2026-03-25","type":"pipeline","source":"GuruFocus","summary":"EXEL: Former Executive Joins Recursion Pharmaceuticals as New CM - GuruFocus","headline":"EXEL: Former Executive Joins Recursion Pharmaceuticals as New CM","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-13","type":"earnings","source":"simplywall.st","summary":"Assessing Exelixis (EXEL) Valuation After Analysts Lift 2026 Earnings Forecasts - simplywall.st","headline":"Assessing Exelixis (EXEL) Valuation After Analysts Lift 2026 Earnings Forecasts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxQUWVvdWttNnBQR0JCVjZ3eE9icGVkNlR3bTB0c0VfbVV4azNXUWc1VFAwYUtyMlFKa01ZdGhySzRnTWpFTXRhQmUxV1BDQjhmMjJNUS11aFdxQXBpSFA0Y240R0FNNEN0cXlXWFlkVHVlRXBYbUxqZkJURERlTWVvbDdIdEc4WXZpVWc1ekNkQnl6bUxvMnF6dWRmX1BvcUxFM29zLXBSR3lzS0pva0h2MDZtWlZBUQ?oc=5","date":"2026-02-13","type":"earnings","source":"TradingView","summary":"Agios Pharmaceuticals Incurs Narrower-Than-Expected Q4 Loss - TradingView","headline":"Agios Pharmaceuticals Incurs Narrower-Than-Expected Q4 Loss","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxOcV91d0xocjJjX0MyR3RUbmNQeVBYaTUwUTIyUm9DZmQ5bWQzaEppel9MU04wQUUxejVPMkFvMTBkV2xNbVBodDctb2NmeDRrU1VyYWhoLUpZeFdkaVpxanh0dEhFLXA5bUp3bWU4VWcyLXlnQXByRWstNmFuTmVFWTlBamJncFpGTzQ4TENQOXg5T2wzT0Rvc0hJcGZwcFVOWGRvVHRoVDFuMWkyVWZSUUY1Z21rd0ZGVTBodGZZeEdLNF9ncmpjNm5IWXdsMHUwSl9QR1FOb182Z9IB3wFBVV95cUxObV83NjRiUjNBcTQydU5VSGRpaURHcUh6Q1RILXF2TThuQzFIQll2Rnk1bG5vME9oNldfOGZPY3BUSldqaG02N040dVlGcEpIODg3ZzA1Nm14VGtMWDh2dDhFY0V4LVNRdFY1bmN3OUZ5eHY3eFZNY0M0STBKb2k2ck9DLWl5YmtRMzNzMjR0RmFhQ2xnbURSY2kwNVM5QVFTcGZVcWJ3M1NDby1ackIwSGkwdXNYVWRRaWRtcWVHbFY0RmY4Y09nX0VHdVZfd1JoZ1lDTEpJNlBPbVltSFpr?oc=5","date":"2026-02-12","type":"pipeline","source":"simplywall.st","summary":"Exelixis (EXEL) Margin Expansion To 33.7% Tests Skeptical Growth Narratives - simplywall.st","headline":"Exelixis (EXEL) Margin Expansion To 33.7% Tests Skeptical Growth Narratives","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxQUzJDQTRnQ2pOU0JoUUJRT2YxYm9Qc3hIaFY4WktwR09HeDFLaVRCQ0dRRzF4RHJ1RnN3cTFVUFUyVzVjVFJjZmpuS3VCbTlpQ1RTQi1OcnhPWFZ1ZUJWTHpDN1hwbW51UGlBdUlFU3NrYzdXSWRob1Y0Q3F1QUs3c3dNcl9sNU16amtjT2lB?oc=5","date":"2026-02-05","type":"pipeline","source":"The Motley Fool","summary":"Best Biotech Stocks of 2026 and How to Invest in Them - The Motley Fool","headline":"Best Biotech Stocks of 2026 and How to Invest in Them","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxQdVhqTnNSWGJqa0NveVAyazdqby1lckhiSFdaY3JFRTJ0UG01X0ZHQkVMbkhqTHJZMEtZQ1VVSnNPSGc0a2cxVnNpY19aLTNXX1VFOFprNU8zUDlvWFhDSEZQRm1oeVVkLV9qZHMwY19ISWJrcXl5dVZKcUIyOTJPd3FucFo1RVFITk9YcWhuM3BILWxELXctZ0lOX3pZMTQ?oc=5","date":"2026-01-16","type":"pipeline","source":"Fierce Pharma","summary":"Exelixis aims to be a top-5 solid tumor drugmaker in the US: CEO - Fierce Pharma","headline":"Exelixis aims to be a top-5 solid tumor drugmaker in the US: CEO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxOOXZ0U1NPVW1NSF9uNkY4enVSUlVFY251Nk9FMUVJU0RqaC1KcWw0eFFqWHlLZDFod240ODAzZ0k5dGJhMm1zUEhMUWpuTkp5N29QQXp1dHYtcFczTWJHV1lTYWI3Tzh1MGVWUGdOVFhjVFlVd084NmJnRWJvc2JPZmVwdVVTdmZFUkRfWFJPeXh6RGc0dkF5OGRMdldZMC16T2VOMU1iTWotTC1MNlh4d0FBUndqcTJyaVl3MXJhUjRuNFhxdElQdFZhMA?oc=5","date":"2026-01-07","type":"pipeline","source":"AD HOC NEWS","summary":"The Truth About Exelixis Inc: Is This Quiet Cancer Stock About To Explode? - AD HOC NEWS","headline":"The Truth About Exelixis Inc: Is This Quiet Cancer Stock About To Explode?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQY0pVY3NvR1VOTXVLSkZ4MFF5OHpjQUoyVU1tVE5DSGp2VDM4YzYySFMxSi1aTlJZT3hkR2h3Yk01RVNIbjc1cVVacHY0aW5mZllXN0ZybWlJb18tOEotU1NuUlJJSndHZVkzS254SDUteFQ2RXNmZWNoQjVYRFl2WFpRM2N6aEVrVkhSTmdreEVaQTZaQkZMdG1kZjEtRUthazhnZFR6ZlY?oc=5","date":"2025-12-02","type":"pipeline","source":"Daily Forex","summary":"Best 7 Biotech Stocks in December 2025 (Chart) - Daily Forex","headline":"Best 7 Biotech Stocks in December 2025 (Chart)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPOVNxWXg4RThyQnUxVmFWWjVfcWNtMnVpbmhjQVhDTmxIN1pZaEpzMGc5VzBqc1AwUmp4YWM1cVp2dGxJYVJicWVQWDgxaUVIQ05Ud0kyZVBnNVg1WFpjUEdwemJpTWdmVkI1MThqTWdfTndHYnlZeEduWERYMjNjS0pZQU1RZkxzLXl2d3RwcG9VUF9KTHBr?oc=5","date":"2025-12-01","type":"deal","source":"The Motley Fool","summary":"2 Under-the-Radar Stocks to Buy Heading Into 2026 - The Motley Fool","headline":"2 Under-the-Radar Stocks to Buy Heading Into 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxPUVl4UF9Ma0JBS3NsUjlXdFl4eVpQMnVhSUhDTnZBQVpHcXA2OTVybGVwWGdHNTRORkdaUmIwM1dXdW8zcm9rVXlBZFJFdEJBTXZxVVBYVFRpaXR1cFF6Q1hmTVZIQTFDUXVrSklkTjdXMzlTa2lGeG9ndFhEQ3NOanJDSkRpbmFPXzctcA?oc=5","date":"2025-10-27","type":"earnings","source":"Insider Monkey","summary":"9 Most Profitable Biotech Stocks to Buy - Insider Monkey","headline":"9 Most Profitable Biotech Stocks to Buy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxQQVZmWHpIa2hjSURSX0xPOHFGM3NINC1LM25mMmJiWTJtRWloQUxDMXpVZXFMWHMzSzNLeXd4Q0lFVUQ3Vk5Ldlhyci10OFRFamF2Y3FvNGIyOFlvM1A5UHB5N2FGNXpEdnFaY1lVVUpNNVN1cGY3WkN0VzRIT0VfeXR1SEZDazhYYUlHaUFn?oc=5","date":"2025-10-20","type":"trial","source":"The Pharma Letter","summary":"Markets uninspired by Exelixis ESMO data - The Pharma Letter","headline":"Markets uninspired by Exelixis ESMO data","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9AFBVV95cUxNT2EwVDA1QTljMDViWTJzbXk0T181bThWYlgtN2preGFOVWk0Vk1sQk9qQzlna2xrcEVjaUNhX3U2LUZ3cnRsRVBDZjdoWmo0TTFWb2dGX1JtUmQ3aUUyOGxsa1VBcU5IaXhwUU0wWGJsZnllaU52TlNrNHhoMXJNSDlQLXpGNUxJWFNhZzAxcXVFalBVWk84WlJLRXNuYS1CbGhVc0tKMzd4cUY0b2VmdngyR0xMeEJacUVCNldNYlh0azI5TDJWX2FOczNCeUJYMkY0WE5wemJDNDNxbmFCb1FKVkIwMFVodExtdV9lZWg1Qm5t?oc=5","date":"2025-10-20","type":"regulatory","source":"Benzinga","summary":"Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga","headline":"Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session","sentiment":"neutral"}],"patents":[{"drugName":"Cabozantinib","drugSlug":"cabozantinib","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":1400000000}],"drugCount":5,"phaseCounts":{"marketed":2,"phase_3":3},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Bayer","Merck & Co.","Pfizer"],"therapeuticFocus":["Oncology"],"financials":{"source":"sec_edgar","revenue":452477000,"revenuePeriod":"2017-12-29","revenueHistory":[{"value":452477000,"period":"2017-12-29"},{"value":120072000,"period":"2017-12-29"},{"value":152510000,"period":"2017-09-29"},{"value":99008000,"period":"2017-06-30"},{"value":80887000,"period":"2017-03-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":825001000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":782570000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":2844423000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":44.27,"previousClose":43.99,"fiftyTwoWeekHigh":49.62,"fiftyTwoWeekLow":32.38,"fiftyTwoWeekRange":"32.38 - 49.62","fiftyDayAverage":42.69,"twoHundredDayAverage":41.59,"beta":0.42,"enterpriseValue":10566414336,"forwardPE":11.3,"priceToBook":5.38,"priceToSales":5.12,"enterpriseToRevenue":4.55,"enterpriseToEbitda":11.46,"pegRatio":0,"ebitda":921756032,"ebitdaMargin":39.7,"freeCashflow":631157120,"operatingCashflow":884267008,"totalDebt":200920000,"debtToEquity":9.3,"currentRatio":3.56,"returnOnAssets":19.3,"returnOnEquity":35.5,"analystRating":"2.1 - Buy","recommendationKey":"buy","numberOfAnalysts":18,"targetMeanPrice":46.83,"targetHighPrice":60,"targetLowPrice":35,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":2.2,"institutionHeldPercent":103.1,"sharesOutstanding":259708689,"floatShares":211444426,"sharesShort":26352704,"shortRatio":8.75,"shortPercentOfFloat":10.2,"epsTrailing":2.78,"epsForward":3.93,"revenuePerShare":8.54,"bookValue":8.23,"officers":[{"age":77,"name":"Dr. Stelios  Papadopoulos Ph.D.","title":"Co-Founder & Independent Chair of the Board"},{"age":64,"name":"Dr. Michael M. Morrissey Ph.D.","title":"CEO, President & Director"},{"age":57,"name":"Mr. Christopher J. Senner","title":"Executive VP & CFO"},{"age":61,"name":"Dr. Dana T. Aftab Ph.D.","title":"Executive Vice President of Research & Development"},{"age":null,"name":"Dr. Brenda J. Hefti J.D., Ph.D.","title":"Senior VP & General Counsel"},{"age":null,"name":"Dr. Anne  Champsaur M.D.","title":"Senior Vice President of Drug Safety"},{"age":null,"name":"Dr. William  Berg M.D.","title":"Senior Vice President of Medical Affairs"},{"age":49,"name":"Mr. Patrick Joseph Haley M.B.A.","title":"Executive Vice President of Commercial"}],"industry":"Biotechnology","irWebsite":"http://www.exelixis.com/investors-media","website":"https://www.exelixis.com","phone":"650 837 7000"}}